Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

First Wave BioPharma, Inc. (FWBI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.1722+0.0057 (+3.42%)
At close: 04:00PM EDT
0.1700 -0.00 (-1.28%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close0.1665
Open0.1660
Bid0.1700 x 1000
Ask0.1750 x 3000
Day's Range0.1640 - 0.1773
52 Week Range0.1350 - 8.5700
Volume1,428,737
Avg. Volume3,211,341
Market Cap7.162M
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-5.6750
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FWBI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • First Wave BioPharma, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • GlobeNewswire

    First Wave BioPharma, Inc. Announces Private Placement

    BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, today announced that it has entered into a securities purchase agreement with several institutional accredited investors for the issuance and sale of (i) an aggregate of 150 shares of its Series D Convertible Preferred Sto

  • GlobeNewswire

    First Wave BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Investment Conference

    Fireside Chat scheduled for Tuesday, May 24, 2022, at 3:00 p.m., EDTBOCA RATON, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today, that James Sapirstein, Chairman and Chief Executive Officer, will participate in a “fireside chat” with Yi Chen, Ph.D., Managing Di

  • GlobeNewswire

    First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

    BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders to provide an update on recent events and an outlook for the Company’s clinical programs

Advertisement
Advertisement